Infectious Diseases: News, Opinions, Training最新文献

筛选
英文 中文
Use of the drug angiovit in hemorrhagic fever with renal syndrome: evaluation of markers of vascular endothelial damage and kidney disfunction 肾综合征出血热患者血管血管炎的应用:血管内皮损伤和肾功能指标的评价
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-4-99-105
G. Latypova, R. Murzabaeva, D.A. Valishin, A. Gilmanov, A.Kh. Lukmanova
{"title":"Use of the drug angiovit in hemorrhagic fever with renal syndrome: evaluation of markers of vascular endothelial damage and kidney disfunction","authors":"G. Latypova, R. Murzabaeva, D.A. Valishin, A. Gilmanov, A.Kh. Lukmanova","doi":"10.33029/2305-3496-2022-11-4-99-105","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-4-99-105","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19 吸附型益生菌在SARS-CoV-2型肺炎综合治疗中的应用效果短期内的生活质量
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-3-69-80
E. Meskina, M. K. Khadisova, T. V. Stashko, L. Galkina, E. E. Tselipanova, I. M. Shilkina
{"title":"Efficiency of application of sorbed probiotics in the complex therapy of pneumonia caused by SARS-CoV-2. Quality of life in the short term COVID-19","authors":"E. Meskina, M. K. Khadisova, T. V. Stashko, L. Galkina, E. E. Tselipanova, I. M. Shilkina","doi":"10.33029/2305-3496-2022-11-3-69-80","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-3-69-80","url":null,"abstract":"Aim. To determine the clinical efficacy and safety of the immobilized (sorbed) probiotics Bifidobacterium bifidum 1 (5×108 CFU) and B. bifidum 1 (5×107 CFU) in combination with Lactobacillus plantarum 8P-А3 (5×107 CFU) in the complex therapy of pneumonia caused by SARS-CoV-2 in adult patients without severe risk factors and their impact on health-related quality of life (QoL). Material and methods. An open, randomized prospective study included 100 patients (45 males, 55 females), aged from18 to 60 years without risk factors for severe COVID-19, with pneumonia confirmed by computed tomography and an area of lung lesion no more than 75% (moderate forms). SARS-CoV-2 RNA in nasal and oropharyngeal swabs (RT-PCR) was detected in 72% of the participants, in the rest it was highiy probable in terms of the aggregate parameters. The publication presents the results of self-assessment (94 respondents) of working capacity limitations, shortness of breath, intestinal disorders since the end of the probiotic regimen (PR: hospitalization period – B. bifidum 1, 3 capsules 2 times a day for 10 days, then after hospitalization – B. bifidum 1 in combination with L. plantarum 8P-А3 2 powders 3 times a day for 14 days) and QoL (Short Form Medical Outcomes Study: SF-36) 1 month after hospitalization. Results. At the end of PR, the ability to engage in daily activities was higher by 23.1% [95% confidence interval 5.3–37.3, OR 0.08 (0.08–0.77)]. Difficulty of breathing during exercise was less common by 29.7% [15.1–44.5%], OR 0.09 [0.02–0.40], hard stools and no bowel movements were recorded less often by 21.3% [8.5–34, 1] for 1–3 days. One month after hospitalization, the QoL of the patients receiving standard treatment was significantly reduced relative to population indicators in Russia. It was more significantly due to the psychological component of health [total measurement 38.1 (36.2–40.0)] and less significantly due to the physical component [49.5 (48.3–50.8)]. The main reasons limiting daily activities [Role Emotional (RE): 39.4 (37.4–41.4)] were decreased vitality [VT: 40.2 (38.9–041.5)], emotional depression [Mental Health (MH): 41.2 (39.4–43.0)], deficit of social contacts [Social Functioning (SF): 45.1 (43.7–46.6)]. The patients who received PR had a higher ability to carry out daily activities [RE: 57.7 (55.6–59.7)], the severity of psychological problems associated with fatigue, anxiety and depression was lower [MH: 59.8 (58.7–60.9), р<0,001]. The effect of the PR on negative perceptions of social isolation was comparatively less [SF: 53.9 (52.2–55.4)]. The QoL of the patients who additionally suffered from diarrhea in the acute period of SARS-CoV-2 pneumonia was worse in comparison with the patients without diarrhea (due to pain and inability to endure physical activity). The effects of immobilized (sorbed) probiotics to the QoL of the patients with diarrhea during the acute period of COVID-19 were most significant. Conclusion. PR had a significant posi","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic criteria for the development of severe clinical forms of COVID-19 in medical organization workers 医疗机构工作人员COVID-19重症临床形式发展的预后标准
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-4-19-29
T. Platonova, T. Semenenko, A. .. Golubkova, E. Sisin, M. Sklyar, E. Karbovnichaya, S. Smirnova
{"title":"Prognostic criteria for the development of severe clinical forms of COVID-19 in medical organization workers","authors":"T. Platonova, T. Semenenko, A. .. Golubkova, E. Sisin, M. Sklyar, E. Karbovnichaya, S. Smirnova","doi":"10.33029/2305-3496-2022-11-4-19-29","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-4-19-29","url":null,"abstract":"Employees of medical organizations are one of the risk groups for infection with a new coronavirus infection (COVID-19), including with the development of severe clinical forms. The aim of the study was to analyze the clinical manifestations of a new coronavirus infection in medical workers with the determination of laboratory markers for the development of severe COVID-19. Material and methods. The study included 186 medical workers who had COVID-19 in 2020. In 67 people (observation group), the disease occurred in the form of pneumonia, in 119 people (comparison group) - acute respiratory infection caused by SARS-CoV-2. In the acute period of the disease, a laboratory examination was carried out: a general clinical blood test, CD-typing of lymphocyte subpopulations, assessment of biochemical parameters, determination of parameters of the hemostasis system and cytokine levels. Using the binary logistic regression method, we have built multifactor models. To determine the threshold values of the indicators, we used ROC analysis. Statistical processing of materials was carried out using Microsoft Office 2016 and IBM SPSS Statistics (version 26). The differences were considered statistically significant at p<0.05. Results and discussion. The most frequent clinical manifestations of COVID-19 were: weakness, fever, myalgia, arthralgia, difficulty in nasal breathing, serous-mucous discharge from the nose, sore throat, cough, feeling of \"tightness\" in the chest, shortness of breath, headache, pain in the eyeballs, dizziness, anosmia, ageusia and dyspeptic manifestations in the form of diarrhea, nausea or vomiting. Markers associated with the development of severe pneumonia associated with COVID-19 have been identified. Threshold values of laboratory parameters for predicting the severe course of COVID-19 were determined: the number of platelets (less than 239x109/l), lymphocytes (less than 1.955x109/l), cytotoxic T-lymphocytes (less than 0.455x109/l), T-helper cells (less than 0.855x109/l), NK-cells (less than 0.205x109/l), ESR (more than 11.5 mm/h), LDH (more than 196 units/l), total protein (less than 71.55 g/l), D-dimer (more than 0.325 mcg/ml), CRP (more than 4.17 mg/l), IL-6 (more than 3.63 pg/l). Conclusion. The data obtained make it possible to predict the possibility of developing a severe variant of the COVID-19 course.Copyright © 2022 Infectious Diseases: News, Opinions, Training. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mixed cryoglobulinemia in chronic hepatitis C: transformation of perceptions in the context of modern antiviral therapy 慢性丙型肝炎混合性冷球蛋白血症:在现代抗病毒治疗背景下观念的转变
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-3-138-150
M. Zubkin, T. Semenenko, V. I. Chervinko, N. Frolova, M. Konopleva, E. Kryukov
{"title":"Mixed cryoglobulinemia in chronic hepatitis C: transformation of perceptions in the context of modern antiviral therapy","authors":"M. Zubkin, T. Semenenko, V. I. Chervinko, N. Frolova, M. Konopleva, E. Kryukov","doi":"10.33029/2305-3496-2022-11-3-138-150","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-3-138-150","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"77 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of the possible association of patients’ genetic factors with course of dengue virus infection 患者遗传因素与登革病毒感染病程的可能关联分析
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-1-8-14
L. I. Nikolaeva, V. F. Larichev, M. A. Saifullin, A. Dedova, A. Grishechkin, A. V. Vasilyev, A. Kozlova
{"title":"Analysis of the possible association of patients’ genetic factors with course of dengue virus infection","authors":"L. I. Nikolaeva, V. F. Larichev, M. A. Saifullin, A. Dedova, A. Grishechkin, A. V. Vasilyev, A. Kozlova","doi":"10.33029/2305-3496-2022-11-1-8-14","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-1-8-14","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Clinical manifestations and emotional disorders in patients with new coronavirus infection (COVID-19) 新型冠状病毒感染(COVID-19)患者的临床表现及情绪障碍
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-2-19-24
L. Ratnikova, V. Ragozinskaya
{"title":"Clinical manifestations and emotional disorders in patients with new coronavirus infection (COVID-19)","authors":"L. Ratnikova, V. Ragozinskaya","doi":"10.33029/2305-3496-2022-11-2-19-24","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-2-19-24","url":null,"abstract":"The Novel Coronavirus Disease (COVID-19) is characterized by a variety of clinical manifestations, including a predominant lesion of the respiratory system with the possible development of distress syndrome, the development of multiple organ failure. COVID-19 can cause depression, anxiety, and other emotional disorders, which may interfere with subsequent physical recovery. The aim – clinical analysis of emotional disorders in patients with the Novel Coronavirus Infection (COVID-19). Material and methods. A retrospective analysis of electronic medical records of 124 patients admitted to the infectious diseases department of Chelyabinsk City Clinical Hospital No. 8 in 2020–2021 was carried out. The methods of clinical and psychological research (including clinical conversation, observation and testing using the “Hospital Scale of Anxiety and Depression” HADS and the “Symptom Check List” SCL-90-R) were used to identify the features of the emotional states of patients with COVID-19. Statistical analysis was performed using the statistical package «Statistica 6.0». The Spearman rank correlation coefficient was used. Results. Typical complaints upon admission to the hospital are fever, cough, general weakness, loss of smell and taste, runny nose. The majority of patients showed elevated levels of C-reactive protein and protein of the acute phase of inflammation – ferritin, an increase in the D-dimer by more than 2.5 times compared with the average standard values, a decrease in the value of the prothrombin index (mean value 88.7±6.4%) indicate coagulopathy as a manifestation of hyperinflammation that develops in COVID-19. More than half of patients (52.08±9.42%) experienced psychological distress of moderate and high severity: an increased level of distress was recorded in 42.78±9.33% of the examined patients, a high level of distress was found in 9.30±5.48% of patients. Direct correlations of varying degrees of strength between general somatic distress and indicators of anxiety, depression, psychopathological manifestations (obsessive-compulsiveness and interpersonal sensitivity) and mental distress were identified. Revealed negative emotional experiences in patients with COVID-19 can cause adverse effects on the course and prognosis of the disease, reduce adherence to treatment, negatively affect the social functioning and quality of life of patients. © Infectious Diseases: News, Opinions, Training 2022.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484207","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Helicobacter pylori: clinical significance and diagnostic principles 幽门螺杆菌:临床意义及诊断原则
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-1-119-129
D. Bordin, M. Shengelia, V. A. Ivanova, I. Voynovan
{"title":"Helicobacter pylori: clinical significance and diagnostic principles","authors":"D. Bordin, M. Shengelia, V. A. Ivanova, I. Voynovan","doi":"10.33029/2305-3496-2022-11-1-119-129","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-1-119-129","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Ricketsiosis (material for the preparation of the lecture) 立克次体病(讲座准备材料)
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-1-130-136
K. Galimzyanov, N.R. Bedlinskaya, A. Akhmineeva, A. G. Guseinova
{"title":"Ricketsiosis (material for the preparation of the lecture)","authors":"K. Galimzyanov, N.R. Bedlinskaya, A. Akhmineeva, A. G. Guseinova","doi":"10.33029/2305-3496-2022-11-1-130-136","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-1-130-136","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Olokizumab reduces the risks of death in hospitalized patients with moderate and severe COVID-19 Olokizumab可降低中重度COVID-19住院患者的死亡风险
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-4-8-18
E. V. Tavlueva, A. E. Markarov, M. Petrushin, A. Vizel’, G. Ignatova, V. Antonov, A. Agaf'ina, B. Bakirov, V.M. Mozgovaya, O. Filon, A. Zinkovskaya, A. Dolgorukova, M. Samsonov
{"title":"Olokizumab reduces the risks of death in hospitalized patients with moderate and severe COVID-19","authors":"E. V. Tavlueva, A. E. Markarov, M. Petrushin, A. Vizel’, G. Ignatova, V. Antonov, A. Agaf'ina, B. Bakirov, V.M. Mozgovaya, O. Filon, A. Zinkovskaya, A. Dolgorukova, M. Samsonov","doi":"10.33029/2305-3496-2022-11-4-8-18","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-4-8-18","url":null,"abstract":"Aim – to evaluate the efficacy and safety of olokizumab in hospitalized patients with moderate to severe coronavirus disease COVID-19. Material and methods. A multicenter non-interventional retrospective study of olokizumab treatment in hospitalized patients with COVID-19 was conducted. The initial population in this study included 2926 patients with COVID-19. Patients with moderate or severe disease who were taking corticosteroids as part of standard therapy were selected for this analysis. The final population was 1738 patients. A test group (standard therapy: corticosteroids, antiviral, pathogenetic or symptomatic therapy in combination with olokizumab) and a comparison group (standard therapy only) were formed. Each group included 869 patients. The primary end point was all-cause mortality from the start of anti-inflammatory therapy to the end of follow-up. We also analyzed the incidence of transfer and the length of stay of patients in the intensive care unit, the duration of hospitalization, as well as the change in C-reactive protein level. Results and discussion. It was found that olokizumab significantly reduces the all-cause mortality compared with standard therapy: 54 (6.21%) cases compared with 111 (12.77%) in the control arm, p<0.001, odds ratio (OR) 2.21 [1.57;3.1]. The results of factor analysis confirmed that olokizumab increases the odds of recovery, OR 2.41 (95% CI 1.64–3.54, p<0.001). In addition, patients in olokizumab group showed significantly lower plasma CRP levels compared with control group. Already on the 2nd day after the start of therapy the CRP level was almost 2 times lower in the olokizumab group than in the control group (the median was 13 [5.6;28.55] mg/l and 25 [15.3;79.25] mg/L in the olokizumab and comparison groups, respectively). Conclusion. The results of the study confirm the clinical data on the efficacy of olokizumab as therapy for COVID-19 patients. © 2022 Tomsk Polytechnic University, Publishing House. All rights reserved.","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical features of bacterial intestinal infections in people over 60 years of age (lecture preparation material) 60岁以上人群肠道细菌感染的临床特点(讲座准备材料)
Infectious Diseases: News, Opinions, Training Pub Date : 2022-01-01 DOI: 10.33029/2305-3496-2022-11-4-112-117
N. Epifantseva, A. N. Emelyanova, E. N. Kalinina, G. Chuprova
{"title":"Clinical features of bacterial intestinal infections in people over 60 years of age (lecture preparation material)","authors":"N. Epifantseva, A. N. Emelyanova, E. N. Kalinina, G. Chuprova","doi":"10.33029/2305-3496-2022-11-4-112-117","DOIUrl":"https://doi.org/10.33029/2305-3496-2022-11-4-112-117","url":null,"abstract":"","PeriodicalId":36113,"journal":{"name":"Infectious Diseases: News, Opinions, Training","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"69484720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信